Literature DB >> 14532210

Use of turbidimetric growth curves for early determination of antifungal drug resistance of filamentous fungi.

Joseph Meletiadis1, Debbie T A te Dorsthorst, Paul E Verweij.   

Abstract

A previously described microbroth kinetic system (J. Meletiadis, J. F. Meis, J. W. Mouton, and P. E. Verweij, J. Clin. Microbiol. 39:478-484, 2001) based on continuous monitoring of changes in the optical density of fungal growth was used to describe turbidimetric growth curves of different filamentous fungi in the presence of increasing concentrations of antifungal drugs. Therefore, 24 clinical mold isolates, including Rhizopus oryzae, Aspergillus fumigatus, Aspergillus flavus, and Scedosporium prolificans, were tested against itraconazole, terbinafine, and amphotericin B according to NCCLS guidelines. Among various parameters of the growth curves, the duration of the lag phase was strongly affected by the presence of antifungal drugs. Exposure to increasing drug concentrations resulted in prolonged lag phases of the turbidimetric growth curves. The lag phases of the growth curves at drug concentrations which resulted in more than 50% growth (for itraconazole and terbinafine) and more than 75% growth (for amphotericin B) after 24 h of incubation for R. oryzae, 48 h for Aspergillus spp., and 72 h for S. prolificans were 4 h longer than the lag phases of the growth curves at the corresponding drug-free growth controls which varied from 4.4 h for R. oryzae, 6.5 h for A. flavus, 7.9 h for A. fumigatus, and 11.6 h for S. prolificans. The duration of the lag phases showed small experimental and interstrain variability, with differences of less than 2 h in most of the cases. Using this system, itraconazole and terbinafine resistance (presence of >50% growth) as well as amphotericin B resistance (presence of >75% growth) was determined within incubation periods of 5.0 to 7.7 h for R. oryzae (for amphotericin B resistance incubation for up to 12 h was required), 8.8 to 11.4 h for A. fumigatus, 6.7 to 8.5 h for A. flavus, and 13 to 15.6 h for S. prolificans while awaiting formal MIC determination by the NCCLS reference method.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14532210      PMCID: PMC254297          DOI: 10.1128/JCM.41.10.4718-4725.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  36 in total

Review 1.  Antifungal drug resistance in Aspergillus.

Authors:  C B Moore; N Sayers; J Mosquera; J Slaven; D W Denning
Journal:  J Infect       Date:  2000-11       Impact factor: 6.072

2.  Inoculum standardization for antifungal susceptibility testing of filamentous fungi pathogenic for humans.

Authors:  E Petrikkou; J L Rodríguez-Tudela; M Cuenca-Estrella; A Gómez; A Molleja; E Mellado
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

3.  Analysis of growth characteristics of filamentous fungi in different nutrient media.

Authors:  J Meletiadis; J F Meis; J W Mouton; P E Verweij
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

Review 4.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

5.  In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

6.  Acquired itraconazole resistance in Aspergillus fumigatus.

Authors:  E Dannaoui; E Borel; M F Monier; M A Piens; S Picot; F Persat
Journal:  J Antimicrob Chemother       Date:  2001-03       Impact factor: 5.790

7.  Comparison of NCCLS and 3-(4,5-dimethyl-2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method.

Authors:  J Meletiadis; J F Meis; J W Mouton; J P Donnelly; P E Verweij
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

8.  Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group.

Authors:  T F Patterson; W R Kirkpatrick; M White; J W Hiemenz; J R Wingard; B Dupont; M G Rinaldi; D A Stevens; J R Graybill
Journal:  Medicine (Baltimore)       Date:  2000-07       Impact factor: 1.889

9.  Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining.

Authors:  C Lass-Flörl; M Nagl; C Speth; H Ulmer; M P Dierich; R Würzner
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

10.  Evaluation of a capacitance method for direct antifungal susceptibility testing of yeasts in positive blood cultures.

Authors:  H C Chang; J J Chang; A H Huang; T C Chang
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

View more
  11 in total

1.  Rapid susceptibility testing of medically important zygomycetes by XTT assay.

Authors:  Charalampos Antachopoulos; Joseph Meletiadis; Emmanuel Roilides; Tin Sein; Thomas J Walsh
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

2.  Bacterial nanoscale cultures for phenotypic multiplexed antibiotic susceptibility testing.

Authors:  Emilie Weibull; Haris Antypas; Peter Kjäll; Annelie Brauner; Helene Andersson-Svahn; Agneta Richter-Dahlfors
Journal:  J Clin Microbiol       Date:  2014-07-02       Impact factor: 5.948

3.  The facilitating effect of blue light on the antifungal agent susceptibilities of passaged conidia from the ocular-derived Fusarium solani species complex.

Authors:  Yujie Cen; Yingyu Li; Pei Zhang; Ziyuan Liu; Chen Huang; Wei Wang
Journal:  Lasers Med Sci       Date:  2022-01-29       Impact factor: 3.161

4.  Aspergillus fumigatus DBM 4057 biofilm formation is inhibited by chitosan, in contrast to baicalein and rhamnolipid.

Authors:  Eva Kvasničková; Vít Paulíček; Martina Paldrychová; Richard Ježdík; Olga Maťátková; Jan Masák
Journal:  World J Microbiol Biotechnol       Date:  2016-09-22       Impact factor: 3.312

5.  Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence.

Authors:  Maiken Cavling Arendrup; Eleftheria Mavridou; Klaus Leth Mortensen; Eveline Snelders; Niels Frimodt-Møller; Humara Khan; Willem J G Melchers; Paul E Verweij
Journal:  PLoS One       Date:  2010-04-09       Impact factor: 3.240

6.  In vitro pharmacokinetic/pharmacodynamic modeling of voriconazole activity against Aspergillus species in a new in vitro dynamic model.

Authors:  R Al-Saigh; A Elefanti; A Velegraki; L Zerva; J Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

7.  Composite survival index to compare virulence changes in azole-resistant Aspergillus fumigatus clinical isolates.

Authors:  Eleftheria Mavridou; Joseph Meletiadis; Pavol Jancura; Saiden Abbas; Maiken C Arendrup; Willem J G Melchers; Tom Heskes; Johan W Mouton; Paul E Verweij
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

8.  Epidemiology of invasive fungal infections in the mediterranean area.

Authors:  Ulrike Binder; Cornelia Lass-Flörl
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-03-31       Impact factor: 2.576

9.  Exploration of anti-Malassezia potential of Nyctanthes arbor-tristis L. and their application to combat the infection caused by Mala s1 a novel allergen.

Authors:  Rohit K Mishra; Vani Mishra; Anand Pandey; Amit K Tiwari; Himanshu Pandey; Shivesh Sharma; Avinash C Pandey; Anupam Dikshit
Journal:  BMC Complement Altern Med       Date:  2016-03-31       Impact factor: 3.659

10.  Spectrum and the In Vitro Antifungal Susceptibility Pattern of Yeast Isolates in Ethiopian HIV Patients with Oropharyngeal Candidiasis.

Authors:  Birhan Moges; Adane Bitew; Aster Shewaamare
Journal:  Int J Microbiol       Date:  2016-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.